Lymphocyte Depleting and Modulating Therapies for Chronic Lung Allograft Dysfunction

Summary

This review evaluates lymphocyte-depleting and immunomodulating therapies for progressive CLAD beyond usual maintenance immunosuppression: anti-thymocyte globulin, alemtuzumab, methotrexate, cyclophosphamide, total lymphoid irradiation and extracorporeal photopheresis. The authors state that most interventions are only temporarily effective, and that, weighing efficacy and side effects, photopheresis, anti-thymocyte globulin and total lymphoid irradiation currently offer the best options. The significance statement notes that interpretation of most results is hampered by the lack of randomised controlled trials.

Details

doi

10.1124/pharmrev.123.000834

pmid

37295951

authors

Bos S, Pradère P, Beeckmans H, Zajacova A, Vanaudenaerde BM, Fisher AJ, Vos R

journal

Pharmacological Reviews

year

2023

volume

75

issue

6

pages

1200-1217

Sources and links

• Publisher record via DOI (primary)
• PubMed 37295951

Related

Links from this record

• reviews: Extracorporeal photopheresis (ECP)
• relates to: Cytotoxic and senescent T cells
• authors affiliated with: KU Leuven BREATHE (Laboratory of Respiratory Diseases and Thoracic Surgery)
• coauthor: Robin Vos
• coauthor: Bart Vanaudenaerde

Linked from (derived)

• author affiliation matches this institution (OpenAlex): Newcastle Lung Transplant Programme (Freeman Hospital and Newcastle University)
• author: Andrew John Fisher
• author: Bart Vanaudenaerde
• author: Robin Vos
• evidence: No therapy of proven benefit for established CLAD

Known gaps in this record

• full text not read (abstract only)
• funding statement and grant numbers
• full text and study-level data (not read)
• funding and conflicts of interest